Receipt of a purchase order by Selvita’s subsidiary under a significant agreement
The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs that on December 21, 2022 the Issuer’s subsidiary – Selvita Inc. received from a biotechnology company based in the United States (the “Client”) a purchase order under a framework agreement concluded with the Client on December 16, 2019 (the “Purchase Order”).
The value of the Purchase Order, which is to be executed over the following 12 months, amounts to EUR 1,239,960 (PLN 5,784,165.40 converted at the average exchange rate of the National Bank of Poland EUR 1 = PLN 4.6648 of December 21, 2022). Under the Purchase Order the subsidiary of the Issuer will provide services in the area of medicinal chemistry and synthetic chemistry to support the Client’s discovery programs.
Considering the value of the Purchase Order, as well as the fact of an extension of significant cooperation with the Client, the Management Board of the Issuer considers the Purchase Order to be significant.
Legal basis: Art. 17.1 of MAR
Representatives of the Company:
- Bogusław Sieczkowski – President of the Management Board
- Miłosz Gruca – Vicepresident of the Management Board